ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    Recruiting, Not yet recruiting, Available Studies | "Hand, Foot and Mouth Disease"

Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02889497
Recruitment Status : Not yet recruiting
First Posted : September 5, 2016
Last Update Posted : September 7, 2016
Sponsor:
Information provided by (Responsible Party):
Beijing Chaoyang District Centre for Disease Control and Prevention

Brief Summary:
This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group and immunogenicity observation group.20000 subjects will receive 2 doses vaccines and be observed for safety among 2 epidemic cycles of HFMD.In the immunogenicity observation group, 900 subjects will be randomly received 3 batches vaccines(2 doses),and blood sampled at days 0 and 56.

Condition or disease Intervention/treatment Phase
Hand Foot and Mouth Disease Biological: the first batch vaccine Biological: the second batch vaccine Biological: the third batch vaccine Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Study Start Date : September 2016
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : September 2019

Arm Intervention/treatment
Experimental: 300 subjects receive the first batch vaccine
300 subjects will be randomly received the first batch vaccine
Biological: the first batch vaccine
Experimental: 300 subjects receive the second batch vaccine
300 subjects will be randomly received the second batch vaccine
Biological: the second batch vaccine
Experimental: 300 subjects receive the third batch vaccine
300 subjects will be randomly received the third batch vaccine
Biological: the third batch vaccine



Primary Outcome Measures :
  1. Evaluate the Rate of Adverse reactions of Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months. [ Time Frame: 24 months ]
    Adverse reactions associated with vaccine will be observed in Children Aged 6-71 Months after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.

  2. Evaluate the seroconversion rate of EV71 antibodies in serum after vaccination. [ Time Frame: 56 days ]
    The seroconversion rate of EV71 antibodies will be evaluated in serum at days 0 and 56.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 71 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 8 Months to 71 Months (Healthy Children or Infants);
  • Providing the subjects' legal identity certificate (birth certificate , residence booklet or ID card) and vaccination certificate, legal guardians can provide legal identity proof (resident booklet or ID card) so that the doctor can determine the subject identity to complete recruitment program;
  • The subjects' guardians are able to understand and sign the informed consent voluntary. Guardians have the ability to use the thermometer ,dividing ruler and can fill out the Diary card ,follow-up card according to requirements;
  • Persist for a 24 months visit.If doubtful HFMD case happen,the subject's guardian should send the subject to the medical institutions at above the county level and report this case to the investigator.The subjects who participate immunogenicity observation group can receive sample collection including blood,throat swab or anal awab according to program requirements.

Exclusion Criteria:

  • Exclusion Criteria for the first dose:

    • Subject with clinical diagnosis or suspect HFMD(Especially the history of herpangina);
    • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine;
    • History of seizures,convulsions or twitching ;Family history of progressive neurological disease;
    • Autoimmune disease or immunologic deficiency.Any prior administration of immunodepressant in last 6month;
    • History of asthma,thyroid ablation,angioneurotic edema, diabetes mellitus or malignant tumour;
    • Alienia,functional asplenia,or any condition that cause asplenia or splenectomy;
    • Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder;
    • Any acute disease or chronic disease attack in last 7 days;
    • Any prior administration of blood products in last 3 month;
    • Any prior administration of attenuated live vaccine in last 15 days , subunit or inactivated vaccines in last 7 days;
    • Fever before vaccination, axillary temperature ﹥37.0℃;
    • Attend Other vaccine or drug clinical trials concurrent in 6 months;
    • Any condition that in the opinion of the investigator。
  • Exclusion Criteria for the second dose:

    • Any exclusion criteria for the first dose happens after been enrolled;
    • Newly HFMD diagnosed patients after been enrolled;
    • Any condition that in the opinion of the investigator or ethics committee think should be eliminated.

Responsible Party: Beijing Chaoyang District Centre for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT02889497     History of Changes
Other Study ID Numbers: cycdc2016-6
First Posted: September 5, 2016    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: August 2016

Keywords provided by Beijing Chaoyang District Centre for Disease Control and Prevention:
vaccine
safety
immunogenicity

Additional relevant MeSH terms:
Hand, Foot and Mouth Disease
Mouth Diseases
Foot-and-Mouth Disease
Stomatognathic Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Coxsackievirus Infections
Enterovirus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs